News / Korea / yonhap_finance
Genencell's Inflated Valuation Scandal Exposes KOSDAQ's Recurring Investment Risks
Health Technology · Biotechnology · yonhap_finance · 2026-09-10
016790, 032800, 038530, 047820, 258830
A biotech firm with minimal revenue secured a 64 billion won valuation based on falsified clinical data, highlighting systemic transparency issues in the KOSDAQ market.
What Happened
Inflated Valuation: Genencell, a biotech firm with only 200 million won in revenue in early 2021, was valued at over 64 billion won based on optimistic expectations for its COVID-19 treatment. Sejong Medical invested over 10 billion won based on this valuation, but subsequent criminal proceedings revealed that the underlying clinical data contained fabricated results and omitted critical side effects.
Cycle of Unfair Trading: The Genencell case exemplifies a recurring pattern in the KOSDAQ market where speculative biotech firms leverage unproven drug development prospects to secure high valuations and capital from listed companies. While influential investors often exit after inflating stock prices, the resulting financial burden and damage are left to individual retail investors.
Chain Reaction of Corporate Failures: Several listed companies involved in Genencell's investment, including KH Feelux and Sejong Medical, have faced delisting or severe financial distress. These investment and M&A activities were frequently orchestrated by individuals previously involved in market manipulation and embezzlement, many of whom continue to operate within the capital markets.
Systemic Trust Crisis: This incident has transcended individual corporate failure to become a broader issue regarding the integrity of the KOSDAQ market and investor protection mechanisms. With allegations of political involvement in the clinical trial approval process, there is growing demand for stricter regulatory oversight and improved transparency to restore market confidence.